Inhibition of heart allograft rejection with mitomycin C-treated donor dendritic cells

Transplantation. 2007 Feb 15;83(3):347-50. doi: 10.1097/01.tp.0000248854.30016.11.

Abstract

We showed previously that dendritic cells (DCs) treated with mitomycin C (MMC) tolerize allogeneic T cells in vitro and this might be mediated by downregulation of CD80, CD86, and ICAM-1. Here we analyze the suppression of the T-cell response induced by MMC-DCs in vivo. Rats injected with allogeneic DCs developed a strong lymph node reaction, whereas MMC-DCs induced no reaction. The same effect was obtained when CD80, CD86, and ICAM-1 expressed by DCs were blocked with antibodies. One injection of donor MMC-DCs strongly prolonged heart allograft survival in a donor-specific manner. Suppression of rejection was also achieved when donor DCs were pretreated with a combination of anti-CD80, anti-CD86, and anti-ICAM-1 antibodies, showing that downregulation of these molecules confers the DCs inhibitory properties. We conclude that allogeneic MMC-DCs specifically inhibit the T-cell response in vivo and that downregulation of CD80, CD86, and ICAM-1 is a potential mechanism of this effect.

MeSH terms

  • Animals
  • Antibodies / pharmacology
  • B7-1 Antigen / metabolism
  • B7-2 Antigen / metabolism
  • Dendritic Cells / drug effects*
  • Dendritic Cells / immunology
  • Dendritic Cells / transplantation
  • Down-Regulation
  • Graft Rejection / prevention & control*
  • Heart Transplantation*
  • Immunosuppression Therapy / methods*
  • Intercellular Adhesion Molecule-1 / metabolism
  • Lymphocyte Activation
  • Mitomycin / pharmacology*
  • Rats
  • Rats, Inbred Strains
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology*
  • Tissue Donors

Substances

  • Antibodies
  • B7-1 Antigen
  • B7-2 Antigen
  • Intercellular Adhesion Molecule-1
  • Mitomycin